Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / Launch batch pendingPeptide · Research use only
Selank
$90CAD
A tuftsin-derived heptapeptide explored in stress-response, GABA-related and intranasal neurobiology research.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Selank, clearly explained.
A tuftsin-derived heptapeptide explored in stress-response, GABA-related and intranasal neurobiology research.
Overview
Selank has a small comparative human study and a wider mechanistic literature, much of it from animal or laboratory models. Independent replication, route-specific safety and clinically meaningful outcomes remain insufficiently established.
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived from the immunomodulatory peptide tuftsin and appears in a limited body of human, animal and laboratory research.- Format
- Nasal spray
- Available strengths
- 10mg
- Batch
- Launch batch pending
- Purity
- Verification pending
Research at a glanceOne small comparative human study plus preclinical mechanistic evidence
Reviewed 31 July 2026View research context Specifications
Product details
- Sequence / identity
- TKPRPGP
- Molecular formula
- C33H57N11O9
- Molecular weight
- 751.9 g/mol
- Storage and handling
- Launch handling specifications will be published with the verified batch record. Protect the sealed research material from direct light in the interim.
Batch documentationLaunch record pending
The batch code, analytical results and handling specifications will publish after verification.
- Batch
- Launch batch pending
- Purity
- Verification pending
Important research-use boundary
This catalogue entry describes a research material, not an approved therapeutic formulation. Published findings do not provide directions for personal use and cannot verify the safety or performance of a separately sourced material.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Anxiety-related measures
A 62-person comparative study reported psychometric outcomes for Selank and medazepam in generalized anxiety disorder and neurasthenia.
Evidence so far: Small single-study human evidenceQuestion 02
Receptor-related signalling
Laboratory and animal work has examined GABA- and NMDA-receptor binding as possible explanatory pathways.
Evidence so far: Mechanistic and animal evidenceQuestion 03
Independent confirmation
The human evidence base is narrow, regionally concentrated and insufficient to establish broad efficacy or long-term safety.
Evidence so far: Major evidence gapProposed mechanism
How researchers are investigating the mechanism.
Laboratory studies have examined Selank in relation to enkephalin degradation and GABA-receptor binding. Animal experiments suggest that administration route and strain can materially change the observed signal, which limits broad interpretation.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Comparative study of 62 patients with generalized anxiety disorder or neurasthenia
- What researchers saw
- Investigators reported similar anxiety-scale changes for Selank and medazepam under the study conditions.
- Why that is not the whole story
- A small single-region study does not establish comparative effectiveness, generalizability or the performance of a different formulation.
Study 02Intranasal and intraperitoneal comparison in two mouse strains
- What researchers saw
- The observed behavioural and receptor-binding changes varied by administration route and mouse strain.
- Why that is not the whole story
- Strain-specific animal findings cannot establish a human clinical outcome or a personal-use protocol.
Evidence gaps
What remains unknown?
- Independent, adequately powered human trials with transparent safety reporting are lacking.
- Long-term safety, pharmacokinetics and formulation comparability remain insufficiently characterized.
- Mechanistic receptor findings do not establish a meaningful outcome in people.
Primary sources
Check the original sources.
- Primary comparative human studyZozulia et al. Selank in generalized anxiety disorder and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096.
- Primary preclinical studyKozlovskii et al. Intranasal and intraperitoneal Selank in mouse strains. Bull Exp Biol Med. 2018. PMID 29787664.
- Compound identity recordPubChem CID 11765600. Selank molecular identity and sequence record.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity